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Background: Stereotactic ablative radiotherapy (SABR) has emerged as a new treatment option for patients with
oligometastatic disease. SABR delivers precise, high-dose, hypofractionated radiotherapy, and achieves excellent
rates of local control for primary tumors or metastases. A recent randomized phase II trial evaluated SABR in a
group of patients with a small burden of oligometastatic disease (mostly with 1–3 metastatic lesions), and found
that SABR was associated with benefits in progression-free survival and overall survival. The goal of this phase III trial
is to assess the impact of SABR in patients with 4–10 metastatic cancer lesions.
Methods: One hundred and fifty-nine patients will be randomized in a 1:2 ratio between the control arm
(consisting of standard of care palliative-intent treatments), and the SABR arm (consisting of standard of care
treatment + SABR to all sites of known disease). Randomization will be stratified by two factors: histology
(Group 1: prostate, breast, or renal; Group 2: all others), and type of pre-specified systemic therapy (Group 1:
immunotherapy/targeted; Group 2: cytotoxic; Group 3: observation). SABR is to be completed within 2 weeks,
allowing for rapid initiation of systemic therapy. Recommended SABR doses are 20 Gy in 1 fraction, 30 Gy in 3
fractions, or 35 Gy in 5 fractions, chosen to minimize risks of toxicity. The primary endpoint is overall survival,
and secondary endpoints include progression-free survival, time to development of new metastatic lesions,
quality of life, and toxicity. Translational endpoints include assessment of circulating tumor cells, cell-free DNA,
and tumor tissue as prognostic and predictive markers, including assessment of immunological predictors of
response and long-term survival.
Discussion: This study will provide an assessment of the impact of SABR on clinical outcomes and quality of
life, to determine if long-term survival can be achieved for selected patients with 4–10 oligometastatic lesions.
Trial registration: Clinicaltrials.gov identifier: NCT03721341. Date of registration: October 26, 2018.
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The oligometastatic state refers to a stage of disease
where a cancer has spread beyond the site of the
primary tumor, but is not yet widely metastatic [1]. In
patients with a limited oligometastatic burden, emerging
evidence suggests that treatment of all sites of disease
with ablative therapies (such as surgery or stereotactic
radiation) can improve patient outcomes, including
overall- and progression-free survival.
Historically, evidence to support the oligometastatic
state has consisted of single-arm, non-randomized stud-
ies without controls. One classic study reported on over
5000 patients with lung metastases from a variety of
primary tumors. In patients who achieved a complete
resection of their lung metastases, 5-year overall survival
(OS) was 36%, better than might be expected for a
cohort of patients with metastatic disease [2]. Similarly,
after radiation, a recent pooled analysis of 361 patients
with oligometastatic lesions treated with radiation
demonstrated a 3-year OS of 56% [3].
It has been suggested the long-term survivals
achieved in patients with oligometastases after ablative
therapies is merely due to the selection of very fit pa-
tients with slow growing tumors, since randomized
evidence to support the oligometastatic paradigm has
been lacking [4, 5]. However, at least four recent ran-
domized phase II trials now provide some supporting
evidence of an oligometastatic state.
Randomized evidence supporting the oligometastatic
state
Two of these four randomized trials were done in the
setting of oligometastatic non-small cell lung cancer
(NSCLC). In both, patients presented with a primary lung
tumor and a limited number of metastatic lesions (1–3 in
one trial, 1–5 in the other), and after initial systemic ther-
apy, patients were randomly assigned to standard palliative
treatments vs. consolidative ablative treatments to all sites
of disease. Both trials were stopped early due to evidence
of efficacy, with the ablative treatments achieving a ~ 3-
fold improvement in progression-free survival (PFS) [6, 7].
Based on these results, the phase III NRG LU-002 trial is
assessing the impact of consolidative ablative therapies on
OS.
A third trial, EORTC 40004, examined the impact of
an ablative therapy (radiofrequency ablation [RFA]) in
patients with colorectal cancer metastatic to the liver. In
this trial, patients with a controlled primary tumor and
fewer than 10 hepatic metastases not amenable to resec-
tion, and with no extra-hepatic disease, were randomized
to systemic therapy +/− RFA to all sites of disease [8].
When initially reported [9], the trial showed no differ-
ence in OS between arms, but with long-term follow-up
(median 9.7 years), a significant difference in OSemerged, with an 8-year OS of 36% in the RFA arm and
only 9% in the systemic therapy arm [8].
The fourth trial, Stereotactic Ablative Radiotherapy for
the Comprehensive Treatment of Oligometastatic Dis-
ease (SABR-COMET) enrolled 99 patients who had
controlled primary solid tumors and up to 5 metastatic
lesions [10–12]. Patients were randomized in a 1:2 ratio
between standard of care (SOC) palliative treatments
(Arm 1) vs. SOC + SABR to all sites of disease (Arm 2).
The primary endpoint was OS, and the trial employed a
randomized phase II screening design, with an alpha of
0.20, in order to provide an initial comparison between
arms. More than 90% of patients enrolled had 1–3
metastases. OS was 28months in Arm 1 and 41months
in Arm 2 (p = 0.09), meeting the primary endpoint of
the trial. PFS was doubled: 6 months in Arm 1 and 12
months in Arm 2 (p = 0.001). SABR was generally well
tolerated, with a 29% rate of grade 2 or higher toxicity,
although the rate of treatment-related grade 5 toxicity
was 4.5%.
Despite this new evidence, many uncertainties remain
regarding the oligometastatic state.
Defining the oligometastatic state
A major unanswered clinical question is the precise def-
inition of the oligometastatic state, namely, how many
metastatic lesions are amenable to ablative therapies that
may benefit the patient.
Many studies have defined ‘oligometastatic’ as 1–3, or
1–5, metastatic lesions, although some have used
broader definitions, including the EORTC 40004 trial
described above that allowed up to 9. For example, one
single-arm phase II trial in patients with NSCLC en-
rolled 24 patients with up to 6 active sites of extracranial
disease, and treated patients with SABR to all active sites
along with erlotinib. The treatment was well-tolerated,
with only two grade 3 toxicities. Median OS was 20.4
months, and median PFS was 14.7 months. A second
study included NSCLC patients with up to 8 lesions, as
long as all could be treated within established dose
constraints [13].
In the setting of brain metastases, recent non-
randomized evidence suggests that patients may benefit
from stereotactic radiotherapy to 4–10 metastatic lesions.
The prospective JLGK0901 trial treated 1194 patients who
had 1–10 metastatic lesions, with a total cumulative vol-
ume of ≤15mL, and treated all with stereotactic radiosur-
gery. The study used a non-inferiority design with a
primary endpoint was OS, comparing patients with 5–10
lesions vs. those with 2–4. Median OS in both groups was
10.8months, meeting the primary endpoint of non-
inferiority (p < 0.0001). Treatment was well-tolerated, with
only 9% of patients in either group experiencing adverse
events of any grade. A separate retrospective study
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10 brain metastases (where 64% had received prior brain
radiotherapy), and concluded that it could be delivered
safely, with no episodes of symptomatic necrosis and a
13% rate of radiographic necrosis [14].
The toxicity of SABR may not depend on the overall
number of lesions, but moreso the doses delivered to
organs at risk. For serial organs, such as the spinal cord,
bronchi, and great vessels, reduction of the maximum
dose of radiation is expected to reduce the risk of
toxicity. For parallel organs, such as the lung, liver and
renal cortex, the risk of toxicity may be mitigated by
ensuring that a critical volume of the organ is spared
from substantial doses of radiation [15]. The typical crit-
ical volume to be spared is about 1/3 of the volume of
the organ. Therefore, this trial will employ dose con-
straints for serial structures that ensure minimization of
high-dose volumes, constraints for parallel structures
that ensure critical volume sparing, and constraints for
dose spillage, to ensure that all SABR plans are highly
conformal.
The application of ablative therapies for patients with
4–10 metastatic deposits appears promising, based on
the encouraging results from randomized trials mostly
enrolling patients with 1–3 lesions and the single-arm
studies evaluating ablative therapies patients with a lar-
ger burden of disease. However, it is likely that as the
number of metastases increases, the risk of further dis-
tant failure (i.e. development of additional metastases
after SABR) will increase, and the risk of toxicity from
SABR will likely increase. As a result, the use of SABR in
such patients might be best in a scenario where the doses
of SABR are lowered to reduce the risk of toxicity, pre-
planning of SABR is required before enrollment, and
SABR is given immediately prior to systemic therapy that
will help to address the risk of occult micrometastases.
In summary, it is unclear if all patients with > 3 oligo-
metastatic lesions benefit from SABR, in terms of
improved OS, PFS, or quality of life. The purpose of this
randomized trial is to assess the impact of SABR on
outcomes in patients with 4–10 oligometastatic lesions.
Methods/design
The objective of this trial is to assess the impact of
SABR, compared to standard of care treatment, on over-
all survival, oncologic outcomes, and quality of life in pa-
tients with a controlled primary tumor and 4–10
metastatic lesions.
Primary endpoint
 Overall Survival
Defined as time from randomization to death
from any causeSecondary endpoints
 Progression-free survival
Defined as time from randomization to disease
progression at any site or death
 Time to development of new metastatic lesions
 Quality of life
Assessed with the Functional Assessment of
Cancer Therapy: General (FACT-G) and the
EuroQol - 5 Dimension - 5 Level (EQ-5D-5L)
 Toxicity
Assessed by the National Cancer Institute
Common Toxicity Criteria (NCI-CTC) version 4
for each organ treated (e.g. liver, lung, bone)
Translational endpoints
 Assessment of circulating tumor cells, cell-free
DNA, and tumor DNA as prognostic and predictive
markers of survival, and for early detection of
progression
 Assessment of immunological predictors of response
and long-term survival
Study design
This study is a phase III multicentre randomized trial.
Participating centres will be tertiary, academic hospitals or
radiotherapy treatment centres in Canada, the United
Kingdom, the Netherlands, and Australia (updated coun-
try list available on ClinialTrials.gov entry NCT03721341).
Patients will be randomized with parallel assignment in a
1:2 ratio between current standard of care treatment (Arm
1) vs. standard of care treatment + SABR (Arm 2) to sites
of known disease (Fig. 1).
Patients will be stratified by two of the strongest prog-
nostic factors, based on a large multi-institutional ana-
lysis [3]: histology (Group 1: prostate, breast, or renal;
Group 2: all others), and type of pre-specified systemic
therapy (Group 1: immunotherapy/targeted; Group 2:
cytotoxic; Group 3: observation).
Inclusion criteria
 Age 18 or older
 Willing to provide informed consent
 Karnofsky performance status > 60
 Life expectancy > 6 months
 Histologically confirmed malignancy with metastatic
disease detected on imaging. Biopsy of metastasis is
preferred, but not required.
 Controlled primary tumor
Defined as at least 3 months since original
tumor treated definitively, with no progression at
primary site
Fig. 1 Study Schema
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 All sites of disease can be safely treated based on a
pre-plan
Exclusion criteria
 Serious medical comorbidities precluding
radiotherapy. These include interstitial lung
disease in patients requiring thoracic radiation,
Crohn’s disease in patients where the
gastrointestinal (GI) tract will receive
radiotherapy, and connective tissue disorders such
as lupus or scleroderma.
 For patients with liver metastases, moderate/severe
liver dysfunction (Child Pugh B or C)
 Substantial overlap with a previously treated
radiation volume. Prior radiotherapy in general is
allowed, as long as the composite plan meets dose
constraints herein. For patients treated with
radiation previously, biological effective dose
calculations should be used to equate previous doses
to the tolerance doses listed below. All such cases
must be discussed with one of the study PIs.
 Malignant pleural effusion
 Inability to treat all sites of disease
 Any single metastasis > 5 cm in size.
 Any brain metastasis > 3 cm in size or a total
volume of brain metastases greater than 30 cc.
 Metastasis in the brainstem
 Clinical or radiologic evidence of spinal cord
compression
 Dominant brain metastasis requiring surgical
decompression
 Metastatic disease that invades any of the
following: GI tract (including esophagus, stomach,
small or large bowel), mesenteric lymph nodes, or
skin
 Pregnant or lactating womenPre-treatment evaluation
Investigations
 History and Physical Examination
Including prior cancer therapies and
concomitant cancer-related medications
 Restaging within 12 weeks prior to randomization:
Brain: CT or MRI for tumor sites with
propensity for brain metastasis. All patients with
brain metastases (at enrollment or previously
treated) require an MRI.
Body: 18-FDG PET/CT imaging is
recommended, except for tumors where FDG
uptake is not expected (e.g. prostate, renal cell
carcinoma). PSMA-PET or choline-PET is
recommended for prostate cancer. In situations
where a PET scan is unavailable, or for tumors
that do not take up radiotracer, CT neck/chest/ab-
domen/pelvis with bone scan required
Spine: MRI required for patients with vertebral
or paraspinal metastases. The MRI needs to image
the area being treated and one vertebrae above
and below as a minimum, but does not need to be
a whole spine MRI unless clinically indicated.
 Liver function tests (AST, ALT, GGT, alkaline
phosphatase), albumin, bilirubin, and INR for
patients with liver metastases
 Pregnancy test for women of child-bearing age
Defining the number of metastases
Counting Metastases
Patients are eligible if there are 4–10 metastatic lesions
present. Each discrete lesion is counted separately. For
patients with lymph node metastases, each node is
counted as one site of metastasis. All known metastatic
lesions must be targetable on planning CT. For patients
where the lesion is only detectable on MRI, fusion of the
MRI with the planning CT is required. There is no limit
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long as dose constraints can be met in the pre-plan. For
parallel organs such as the liver and lung, patients with
several lesions may not meet the pre-plan criteria and
therefore will not be randomized.
Previously treated metastases
Patients with prior metastases that have been treated with
ablative therapies (e.g. SABR, surgery, radiofrequency
ablation) are eligible, as long as those metastases are
controlled on imaging. In that case, the previously treated
lesions are counted toward the total of 10 (e.g. a patient
with 3 previous brain metastases treated is allowed to have
up to 7 other metastases for enrollment).
If a patient has received systemic therapy and the
number of metastases has been reduced, they are eligible
for enrollment as long as the total number of metastases
prior to systemic therapy was 10 or fewer.
Small or indeterminate lesions
When patients have small indeterminate nodules (e.g. a
3 mm lung nodule) it can be difficult to determine
whether these are benign or whether they represent me-
tastasis. Any such indeterminate lesion is automatically
considered to be a metastasis unless there are > 2 months
of documented stability. The presence or absence of such
indeterminate lesions will be noted on the study enroll-
ment form.
If a lesion is too small to treat due to targeting issues
(e.g. a 3 mm lung lesion not likely to be visible on cone
beam CT [CBCT]), the following approach is to be
taken: if randomized to Arm 1, no intervention is
needed, since such a lesion would not require palliative
radiation. If randomized to Arm 2, the lesion is followed,
and upon progression to a size that is treatable, it should
be treated with SABR. This would not be counted as
progression.
Brain metastases at presentation
If a patient presents with 1–3 brain metastases and abla-
tion of those metastases (with surgery or radiation) is
judged to be clinically required regardless of the treat-
ment of extracranial metastases, it is permitted. Those
treated metastases count within the total number of 10
lesions. The patient would then be randomized to treat-
ment of the extracranial disease or not.
Patients already receiving systemic therapy
If a patient is already receiving systemic therapy, they
are still eligible for enrollment. For example, if a patient
with 5 metastases has been on pemetrexed for a year
and is planning to continue, they can still be random-
ized, and if allocated to the standard arm would con-
tinue to receive pemetrexed; on the experimental armSABR would be delivered between cycles, possibly
requiring a break in systemic therapy to comply with the
timing of systemic therapy described in the Systemic
therapy section.
Interventions
Standard arm (arm 1)
Radiotherapy for patients in the standard arm should
follow the principles of palliative radiotherapy, for the
purpose of alleviating symptoms or preventing imminent
complications. Recommended dose fractionations in this
arm will include 8 Gy in 1 fractions, 20 Gy in 5 fractions,
and 30 Gy in 10 fractions. Patients in Arm 1 should not
receive stereotactic doses or radiotherapy boosts, unless
there is a clearly known clinical benefit (e.g. stereotactic
radiation to new brain metastases when all disease is
controlled on systemic therapy).
Systemic therapy will be pre-specified based on the
standard of care approach for that patient, and it may in-
clude systemic therapy (cytotoxic, targeted, hormonal, or
immunotherapy) or observation. See Brain metastases at
presentation section for the timing of systemic therapy.
Experimental arm (arm 2)
Stereotactic radiation in Arm 2 will be delivered with
three major guiding principles:
 Minimization of Toxicity: The SABR doses used
herein are lower than those used for radical treatments,
and normal tissue tolerance doses will never be
exceeded. Concurrent chemotherapy or targeted
therapy at the time of radiotherapy is not allowed.
 Minimization of Treatment Time. To avoid delays
in proceeding to systemic therapy, all SABR will be
delivered over the course of 2 weeks.
 Pre-planning required before enrollment: To
ensure safety, all patients require a pre-plan of their
SABR treatments before enrollment. If a patient
undergoes pre-planning but cannot be randomized
due to failure to generate an acceptable plan, the
centre will receive modest compensation to cover
pre-planning costs. The baseline information of such
patients will be captured (i.e. the Eligibility Checklist
and Baseline Form), but they will not be followed for
outcomes.
Dose/fractionation
Each lesion may be treated with 1, 3, or 5 fractions, de-
pending on the local practice of the enrolling institution
and treating physician. All doses are prescribed to the
periphery of the planning target volume (PTV).
Acceptable fractionations are listed in Table 1. Three-
fraction regimens will deliver a fraction every second day,
and five-fraction regimens are delivered daily. All
Table 1 Allowable doses and fractionations*
Number of
Fractions
Preferred
Dose
Acceptable
Doses
Major Deviation
1 20 Gy 16–24 Gy < 16 Gy or > 24
Gy
3 30 Gy 24–33 Gy < 24 Gy or > 33
Gy
5 35 Gy 25–40 Gy < 25 Gy or > 40
Gy
*Note that centres should use doses that standard at their institutions based
on the specific clinical situation, within these guidelines. For example, if the
standard dose for a 2.5 cm brain metastasis is 24 Gy in 3 fractions, which is an
‘acceptable dose’, that should be used instead of the ‘preferred dose’
Palma et al. BMC Cancer          (2019) 19:816 Page 6 of 15treatments must be completed within 2 weeks (10 working
days) in order to avoid delays in starting systemic therapy.
Immobilization
Immobilization will be as in the original SABR-COMET
trial protocol [11, 12].
Imaging/localization/registration
Patients will undergo planning CT simulation with axial
CT images obtained throughout the region of interest.
For centres using stereotactic radiosurgery platforms,
real-time tumor tracking and orthogonal imaging
systems are permitted.
Patients treated at the VUmc in Amsterdam may be
treated with MRI-guided delivery if deemed appropriate
by the treating oncologist, using daily plan adaption as
has been described previously [16–19]. The "4D-CT pro-
cedures" section will not apply to these patients.
4D-CT procedures
4-dimensional CT will be used for tumors in the lungs,
liver, or adrenals. 4D-CT quality assurance procedures
are as per the previous SABR-COMET trial [11, 12].
Volume definitions (arm 2)
For all lesions, the gross tumor volume (GTV) will be
defined as the visible tumor on CT and/or MRI imaging
+/− PET. No additional margin will be added for micro-
scopic spread of disease (i.e. Clinical Target Volume
[CTV] = GTV). For vertebral body lesions, although
some centres consider the entire vertebral body as the
CTV, that is not preferred in this trial due to the risk of
large cumulative amounts of bone marrow being irradi-
ated. It is strongly preferred that vertebral PTV volumes
consist of the GTV (as defined on CT and MRI) with a
small margin for motion, and NOT include the whole
uninvolved vertebral body. A Planning Target Volume
(PTV) margin of 2–5 mm will be added depending on
site of disease, immobilization, and institutional set-up
accuracy: 2 mm margins should be used for spinalstereotactic treatments, 0–2 mm for brain tumors, and 5
mm for other sites.
Targets should be named based on the organ involved,
and numbered cranially to caudally for each organ. For
example, in a patient with 1 brain and 3 lung lesions, no-
menclature would be: GTV_brain_1, GTV_lung_1,
GTV_lung_2, and GTV_lung_3, and corresponding
PTV_brain_1, PTV_lung_1, PTV_lung_2_, and PTV_
lung_3, representing the lesions from superior to
inferior.
For spinal lesions, a pre-treatment MRI is required to
assess the extent of disease and position of the cord.
This must be fused with the planning CT scan. A Plan-
ning Organ at Risk Volume (PRV) expansion of 2 mm
will be added to the spinal cord, and dose constraints for
the spinal cord apply to this PRV. Alternatively, the
thecal sac may be used as the PRV. For radiosurgery
platforms, a PRV margin of 1 mm is permitted for the
spinal cord.
Organ at risk (OAR) doses
OAR doses are listed in Additional file 1. OAR doses
may not be exceeded. In cases where the PTV coverage
cannot be achieved without exceeding OAR doses, the
PTV coverage is to be compromised. All OARs within 5
cm of the PTV must be contoured. This should be tested
for each PTV by creating a 5 cm expansion to examine
which OARs lie within that expansion.
Treatment planning
Treatment can be delivered using static beams (either
3D-conformal radiotherapy or intensity-modulated) or
rotational therapy (volumetric modulated arc therapy, or
tomotherapy). Priority will be placed on generating
clinically acceptable plans while minimizing complexity,
planning time, and treatment time.
Dose constraints may not be exceeded If a dose con-
straint cannot be achieved due to overlap of the target
with an organ at risk, the dose can be reduced, the num-
ber of fractions can be increased, or the target coverage
compromised in order to meet the constraint. The
decision as to whether to reduce the dose to the whole
target, or part of the target (i.e. by compromising the PTV
coverage), is left to the discretion of the treating physician.
In cases where the target coverage must be reduced, the
priority for dose coverage is the GTV (e.g. attempt to
cover as much of the GTV as possible with the prescrip-
tion dose). For vertebral tumors, note that the spinal cord
constraints apply to the PRV (see the "Volume definitions
(arm 2)" section).
For all targets, doses should be prescribed to 60–90%
isodose line surrounding the PTV, and all hotspots
should fall within the GTV. 95% of the PTV should be
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should be covered by 90% of the prescription dose.
Doses must be corrected for tissue inhomogeneities.
Several non-overlapping 6/10 MV beams (on the order
of 7–11 beams) or 1–2 VMAT arcs combined possibly
with a few non-coplanar beams should be utilized. Non-
coplanar beams can be used to reduce 50% isodose
volume.
The number of isocentres is at the discretion of the
treating physician, physicists, and dosimetrists. Gener-
ally, metastases can be treated with separate isocenters if
they are well-separated.
The scheduling and sequence of treating each metasta-
sis is at the discretion of individual physicians, but in
general should begin with the brain, due to risks associ-
ated with progression. All SABR must be completed
within 2 weeks.
Quality assurance (arm 2)
In order to ensure patient safety and effective treatment
delivery, a robust quality assurance protocol is incorpo-
rated. The following requirements must be completed
for each patient:
 Prior to treatment, plans for each patient must be
peer-reviewed, either by discussion at quality
assurance (QA) rounds or by another individual
radiation oncologist.
 All radiotherapy plans must meet target dose levels
for organs at risk (Additional file 1). Prior to plan
approval, the dose to each organ at risk must be
verified by the physicist or treating physician.
 All dose delivery for intensity-modulated plans
(including arc-based treatments) will be confirmed
before treatment by physics staff.
Systemic therapy
Patients treated with prior systemic therapy are eligible
for this study, however, systemic therapy agents that are
cytotoxic, immunotherapeutic, or molecularly targeted
agents are NOT allowed within the period of time com-
mencing 2 weeks prior to radiation lasting until 1 week
after the last fraction. Hormone therapy is exempted
from this and is allowed during treatment. Use of
chemotherapy schemes containing potent enhancers of
radiation damage (e.g. gemcitabine, doxorubicin) are
discouraged within the first month after radiation.
Concurrent steroid treatment for brain metastases
Patients who require systemic steroids as treatment for
brain metastases or related edema should be tapered as
quickly and as safely possible. Prolonged use of steroids
should be avoided, and steroid use will be recorded.Further radiotherapy for progressive disease at new
metastatic sites
Patients in Arm 1 who develop new, untreated meta-
static deposits should be treated with standard-of-care
approaches. SABR to those sites is not permitted, except
for unique scenarios where it would be considered
standard of care (e.g. all disease controlled on systemic
therapy with a newly developed brain metastasis).
Patients in Arm 2 who develop new, untreated meta-
static deposits should be considered for SABR at those
sites, as appropriate, if such deposits can be treated
safely with SABR, and if the treating institution offers
SABR for that body site. If SABR is not possible, then
palliative RT can be delivered if indicated. Patients in
Arm 2 who develop progression at lesion previously
treated with SABR may be considered for palliative
radiation or repeat SABR if safe and dose constraints
can be met.
Quality assurance for centres joining study
Prior to opening the study, each participating research
centre will be required to send to one of the Principal
Investigators a mock treatment plan for the anatomic
sites that will be treated (e.g. lung, brain, liver, adrenal),
to ensure that the treatment plans are designed in com-
pliance with the protocol. The principal investigators
will provide pertinent CT datasets. Alternatively, a pre-
plan for a patient enrolled on this trial may be used for
credentialing. Each participating research centre can
choose which tumor sites will be treated at their individ-
ual centre (i.e. some centres may only choose to treat a
subset of the eligible metastatic sites). Sites that have
prior accreditation for SABR through a clinical trial (e.g.
SABR-COMET, or organ-specific SABR trials) are
exempt from this requirement for the organ sites that
have been accredited in those trials.
Subject discontinuation / withdrawal
Subjects may voluntarily discontinue participation in the
study at any time. If a subject is removed from the study,
the clinical and laboratory evaluations that would have
been performed at the end of the study should be
obtained. If a subject is removed because of an adverse
event, they should remain under medical observation as
long as deemed appropriate by the treating physician.
Follow-up evaluation and assessment of efficacy
Follow-up Prior to Progression
Patients will be seen every 3 months post-randomization
for the first 2 years, and every 6 months until 5 years
after treatment (Table 2). At each visit, a history and
physical examination will be conducted by the oncolo-
gist, and CTC-AE toxicities recorded. The FACT-G and
Table 2 Follow-up Evaluations
Test and Procedures 1–4 weeks
post SABR
treatment
and prior
to
systemic
therapy
3 Months post
Randomization
Years 1–2 Years 3–5 First
progression or
study
completion (at
5 years post-
randomization)
whichever is
first
Every 3 months Every 6 months
History and Physical including assessment of side affects X X
CT or MR head, CT chest, abdomen, pelvis X X
Bone Scan X X
Completion of questionnaires (FACT-G and EQ-5D-5 L) X X
Blood Samples for Correlative Studies (i.e studies that
are associated with the main study)
X (Arm 2) X (Arm 1 & 2) X (Arm 1 & 2)
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pleted at each visit.
CT head (or MR head), CT chest, abdomen and pelvis,
and bone scans will be repeated every 3 months for the
first 2 years, then every 6months until 5 years have
elapsed. Head imaging can be omitted for histologies
without a propensity for brain metastases (e.g. prostate),
and bone scans may be omitted in patients without bone
metastases at presentation. PET scanning may be used
in follow-up for patients who were staged with a PET
scan for trial entry. In such cases, the PET replaces the
CTs of the chest, abdomen, pelvis and the bone scan;
brain imaging would still be required for histologies with
a propensity for brain metastases.
Since many patients will be receiving systemic therapy
and separately-timed imaging may be required to assess
response to systemic therapy, attempts should be made
to avoid duplication of scans. The imaging requirements
herein may be adjusted by ±4 weeks in order to align
with scans used to assess response to systemic therapy.
Follow-up after progression
After progression, patients randomized to Arm 2 will be
considered for salvage SABR if new sites of disease
develop, as long as it can be delivered safely, and to a
maximum of 10 lesions total (including lesions treated
at baseline).
After progression, for patients in either arm, additional
visits, imaging or laboratory investigations should be car-
ried out at the discretion of the oncologist. Additional
treatment (e.g. further systemic therapy) is at the discre-
tion of the treating oncologists. However, additional
treatments, toxicities of study treatment, vital status and
quality of life should still be collected, along with any
further anti-cancer treatment delivered (e.g. further pal-
liative radiation or systemic therapy), and this may be
ascertained remotely (e.g. by phone or mail) to minimize
visit burden for patients.Assessment of efficacy
 Overall Survival
Defined as time from randomization to death
from any cause
 Progression-free survival
Defined as time from randomization to disease
progression at any site or death.
Progression is defined as per the Response
Evaluation Criteria in Solid Tumors (RECIST) 1.1
guidelines (http://recist.eortc.org/recist-1-1-2/). It
can be difficult to distinguish recurrence from
fibrosis/pseudoprogression after stereotactic
radiation in some locations, such as the lung or
brain. In such cases, if the RECIST 1.1 criteria for
progression are met, the situation should be
counted as progression unless there is imaging
follow-up with stability of the imaging findings for
at least 6 months.
As per RECIST 1.1, when findings of
progression are equivocal (e.g. small new lesions of
uncertain etiology), the patient should still be
followed. If progression is confirmed at the next
assessment, the date of progression assigned is the
earlier date when progression was first suspected.
 Time to development of new metastatic lesions
Defined as the time from randomization to
the development of new lesions that were not
detectable at the time of randomization. In a
situation where indeterminate lesions were
present at randomization, progression at one of
those lesions does not count as a new
metastatic lesion.
As noted above, as per RECIST 1.1, when
findings of new metastases are equivocal (e.g.
small new lesions of uncertain etiology), the
patient should still be followed. If progression is
confirmed at the next assessment, the date of
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progression was first suspected.
 Quality of life
Assessed with the Functional Assessment of
Cancer Therapy: General (FACT-G) and the
EQ-5D-5 L
 Toxicity
Assessed by the National Cancer Institute
Common Toxicity Criteria (NCI-CTC) version 4
for each organ treated (e.g. liver, lung, bone)]
Statistical considerations
Randomization
The study will employ a 1:2 randomization between
Arm 1: Arm 2, based on the stratification factors
described in Methods/design section. Patients will be
randomized in permuted blocks, with the size of the
blocks known only to the statistician. The randomization
sequence is known only to the statistician and uploaded
into a restricted-access database (REDCap) housed on
secure hospital servers at LHSC. Upon enrollment of a
patient, the database will be accessed by the trial co-
ordinator to obtain the next intervention in the random
sequence, for the pertinent stratum, which will then be
assigned to the patient.
Sample size calculation
The sample size calculation is based on the OS results in
the SABR-COMET trial. Overall, in that trial, median
OS was 28 months in the standard arm and 41months
in the SABR arm. In the patients with 4–5 metastases,
median OS in that trial was 7 months in the standard
arm and 14 months in the SABR arm. These latter num-
bers are not reliable, since the number of patients with
4–5 metastases was very small, but they are useful to
illustrate that the expected OS will decrease as the
number of lesions increases.
In this current trial, we hypothesize that the median
OS will be 10 months in Arm 1 and 17months in Arm
2. In order to detect this difference, with an alpha of
0.05, 80% power, and a 5% dropout rate, 159 patients
will be required. The study projects accrual over 60
months with 12months of additional follow-up. Analysis
will take place at least 12 months after the last patient is
accrued, once 122 total OS events have occurred.
Analysis plan
Patients will be analyzed in the groups to which they are
assigned (intention-to-treat). De-identified data (except
for study number and initials, see confidentiality below)
will be transmitted from participating centres via RED-
Cap to be collected centrally where it will be stored on
secure hospital servers at LHSC. Source documents will
also be uploaded. Research coordinators (clinical trialsstaff) will perform data checks throughout the trial
period and will call participating centres or visit as ne-
cessary. PFS and OS will be calculated using the Kaplan-
Meier method with differences compared using the
stratified log-rank test. Pre-planned subgroup analyses
will occur based on the stratification factors. A Cox mul-
tivariable regression analysis will be used to determine
baseline factors predictive of survival endpoints. For the
endpoint of time to new metastases, a Fine and Gray
competing risk analysis will be used to account for com-
peting risk of death. Quality of life at 6 months will be
measured using FACT-G and EQ-5D-5 L scores, with
differences between groups tested using the Student’s t-
test. Differences in rates of grade 2 or higher toxicity be-
tween groups will be tested using the Fisher’s Exact Test
or Chi-Squared test, as appropriate.
Data safety monitoring committee
The DSMC membership will be independent of the
study sponsor and free of competing interests. The
DSMC will meet annually after study initiation to review
toxicity outcomes. If any grade 3–5 toxicity is reported,
the DSMC will review the case notes to determine if
such toxicity is related to treatment. If the DSMC deems
that toxicity rates are excessive (> 40% grade 3 toxicity,
or > 8% grade 5 toxicity), then the DSMC can, at its
discretion, recommend cessation of the trial, dose ad-
justment, or exclusion of certain treatment sites and/or
delivery techniques that are deemed as high-risk for
complications.
Interim analysis
The DSMC will conduct one interim analysis once the
75th patient is accrued and followed for 6 months. For
this interim analysis, the DSMC will be blinded to the
identity of each treatment arm, but median OS data will
be presented for each arm. The DSMC will recommend
stopping the trial if there is an OS difference that is
statistically significant with a threshold of p < 0.001
using the stratified log-rank test.
It is deemed worthwhile to stop for futility if both the
OS and PFS analyses are likely to be negative. Therefore,
at this interim analysis, if the hazard ratios for OS and
PFS in Arm 2 vs Arm 1 are BOTH > 1.0 (i.e. a higher
hazard rate for OS in the experimental arm, and a higher
hazard rate for PFS in the experimental arm) using uni-
variable Cox regression, then the trial will be stopped for
futility.
Future pooled analysis with SABR-COMET-3
A separate but similar phase III trial, but for patients
1–3 metastases, called SABR-COMET-3, is being pro-
posed and drafted at the same time as this current
trial. Once both trials are complete, a separate pooled
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will be conducted, with the primary endpoint of OS,
and any of the secondary endpoints from either trial
where data has been collected in both trials.
Biomarker studies
The mandatory translational component of this trial has
been designed to minimize the impact on patients while
addressing important research questions around the oligo-
metastatic state. Specifically, the increased requirements,
beyond standard of care testing, consist of drawing 3 tubes
of blood at 3 time periods (Fig. 2) for all patients: at
randomization, 3-months post-randomization, and at
progression.
Patients in Arm 2 only also require a blood draw 1–3
days after their first fraction of SABR and then 1–4 weeks
after completion of SABR, prior to systemic therapy. In
patients who do not progress, the final sample will be
drawn at study completion (5-years post randomization).
Blood sample collection must take place on Monday,
Tuesday, Wednesday or Thursday such that biospeci-
mens requiring immediate overnight shipping (CTCs)
can be received and processed quickly, without samples
sitting unprocessed over a weekend.
Specimens 1A and 1B are required only for patients in
Arm 2 and consist of 2 tubes of blood for ctDNA
(plasma) and peripheral blood mononuclear cells
(PBMCs). The timing of these blood draws can be
chosen to minimize visits for the patient, but must occur
within 1–3 days after the 1st fraction of SABR and 1–4
weeks post-SABR (prior to systemic therapy), respect-
ively. For example, since many patients will likely be re-
ceiving multiple single-fraction treatments over > 1 day
or will be receiving 3- or 5-fraction SABR, the 1A blood
draw can be completed upon a patient’s return for the
second SABR treatment. This blood draw is preferred toFig. 2 Peripheral Blood Collection Timeline. Study completion is defined as
ctDNA and peripheral blood mononuclear cell isolationoccur on the day after the first fraction. Similarly, since
many patients will be proceeding to systemic therapy
within a few weeks of SABR, completing the 1B blood
draw on the first day of systemic therapy, but prior to
the delivery of the systemic therapy, would be
reasonable.
In addition to blood samples, the study will collect
tissue samples from previous biopsies or resections of
the primary tumor and metastases, where available. No
additional biopsies will be needed for the purposes of
the biomarker component of this trial beyond those col-
lected as part of routine clinical care. If formalin-fixed
paraffin-embedded (FFPE) tissue blocks are not available
to be sent at the discretion of the local pathologist (e.g.
insufficient tissue, or a need to keep all tissue for future
purposes), the FFPE tissue blocks are not required and
centres can proceed by sending peripheral blood only.
Laboratory support and shipping
Each participating institution will require an on-site
laboratory for peripheral blood sample processing. This
laboratory must also have freezer storage (− 80 °C and
liquid nitrogen). The protocols for collection and pro-
cessing of peripheral blood, including required equip-
ment and reagents, are provided in the Laboratory
Manual. All shipping costs will be covered via the
provision of pre-paid shipping labels, and an additional
small stipend will be provided to cover laboratory time.
A ‘biomarker studies kit’ containing collection tubes and
pre-paid shipping labels will be sent to each participating
institution to be retained by the personnel responsible
for biospecimen collection.
Translational studies: Background & Rationale
At the present time, there are no biomarkers that define
the oligometastatic state. The closest to a defining5 years of follow-up. Sample 1A & 1B will include 2 vials of blood for
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kidney, and prostate are associated with improved OS in
patients with clinical oligometastatic disease [3]. Key
clinical characteristics - colloquially termed ‘The Four
Aces’ [20] - help to identify a patient sub-population
with metastatic cancer that is most likely to benefit from
ablation of all sites of disease.
Even within this group, however, outcome can be vari-
able: while some patients exhibit long disease-free inter-
vals and better-than-expected overall survival following
ablation of metastases, others progress rapidly and
extensively with poor survival outcomes [21]. Elucidating
the biological mediators underlying a more indolent,
sequential pattern of progression (i.e., oligometastasis)
versus rapid, “poly-metastatic” progression will allow for
more accurate selection of patients whose intrinsic
natural history of disease make them more likely to
benefit from ablation.
Specific biological characteristics of oligometastatic
disease could provide important predictive biomarkers
in this setting, but have thus far remained elusive. Stud-
ies up to this point have focused on micro-RNA profil-
ing, but unfortunately these studies have not identified
an miRNA expression signature that consistently defines
patients with few metastases [22–24]. No other studies
to our knowledge have sought to identify specific bio-
markers of oligometastasis. While a wide array of pre-
clinical analyses have identified genetic and epigenetic
alterations associated with metastasis in general [25], it
remains to be determined which of these features repre-
sent useful biomarkers in differentiating rapid and
widely metastatic cancer from an oligometastatic natural
history.
Translational studies: purpose
To assess the correlation between candidate biomarkers
of oligometastatic disease (blood- or tissue-derived) and
oncologic outcomes including response to SABR, disease
progression, and overall survival.
Methodology: the liquid biopsy
To evaluate potential biomarkers in a clinical setting, the
use of a “liquid biopsy” is less invasive and more prac-
tical alternative to repeat biopsies. A liquid biopsy refers
to sampling of peripheral blood to isolate and
characterize circulating tumor DNA (ctDNA), circulat-
ing tumor cells (CTCs), and/or circulating host immune
cells, among others [26]. Liquid biopsy is an ideal sam-
pling technique in this clinical trial because biopsy of
metastatic lesions is not always possible, and unlike
metastectomy, SABR does not inherently yield tissue.
Moreover, there is evidence that post-SABR anti-tumor
immune activation can be detected in the peripheral
blood [27] and that tumor necrosis (the immunogeniccell death mechanism associated with SABR) is associ-
ated with greater ctDNA concentrations [28], thus mak-
ing liquid biopsy a rational means by which to assess
potential biomarkers longitudinally.
Despite its many potential advantages, liquid biopsy
does have some drawbacks, including the fact that dis-
cordance has been observed between genotyping via
ctDNA versus tumor tissue; however, this may merely
reflect clonal or temporal heterogeneity [29]. Thus, for
genetic analysis, we propose a combined approach that
capitalizes on published findings of large-scale whole-
genome sequencing efforts (including multi-region se-
quencing studies) [25, 28, 30, 31] to inform: (a) targeted
panel-based evaluation of FFPE tumor tissue (primary
tumor and/or metastasis biopsy) to assess genetic loci
that are most frequently altered in metastatic disease
(mutation or copy-number variation), followed by; (b)
downstream analysis of peripheral blood that is tailored
to detect tumor genetic alterations previously detected
in (a) or more broadly assessed for copy number alter-
ation and mutation (panel-based approach).Circulating tumor cell analysis
Circulating tumor cells have repeatedly demonstrated
their utility as a clinical prognostic metric. Prospective
clinical studies have provided evidence that CTCs are
prognostic in metastatic breast, prostate, and colorectal
cancer, whereby increasing concentration correlates with
oncologic outcomes such as treatment response and sur-
vival [26]. Recently, the largest pooled CTC analysis to
date revealed that CTC enumeration identifies an indo-
lent subgroup of metastatic breast cancer patients (Stage
IVindolent) with improved survival, independent of treat-
ment or molecular subtype [32]. The role of CTCs in
oligometastatic disease has not been studied, yet the
sub-population with slowly-progressing natural history
may overlap with the clinical definition of oligometasta-
sis. Thus, CTCs may represent a useful prognostic and/
or predictive biomarker and their evaluation in this
setting is warranted.Analysis
A peripheral blood sample will be collected at each
participating institution into provided CellSave blood
collection tubes (Menarini Silicon Biosystems; preferred)
or Cell-Free DNA BCT® blood collection tubes (Streck)
which stabilize CTCs for 96 h at room temperature.
Samples will then be prepared for CTC analysis using
the CellSearch system (Veridex, Inc.) in the laboratory of
Dr. Alison Allan. Participating institutions will ship sam-
ples within 24 h to LHSC for processing and CellSearch
analysis.
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The role of the host immune system in establishing a
prohibitive or permissive microenvironment for metastatic
colonization is increasingly well-established: while activa-
tion of cytotoxic T-lymphocytes is thought to inhibit
metastases, regulatory T-lymphocytes can conversely ex-
haust/de-activate anti-tumor immunity, thus having the
opposite effect [33]. Additionally, recent evidence suggests
that natural killer cells contribute to non-specific immune
surveillance to create an inhospitable milieu for the estab-
lishment of metastatic colonies [34]. Furthermore, as
evidenced by the successful application of immune-
checkpoint inhibition in treating metastatic cancer, the
modulation of the host immune system can dramatically
impact the extent of metastasis. Finally, both pre-clinical
and clinical data demonstrate that immune cell activity
can also be modulated by SABR [35], an effect that can be
monitored in peripheral blood via analysis of circulating
immune cells following radiotherapy [27]. SABR may also
effect a so-called abscopal (out-of-field) response, thereby
improving control of metastatic disease [36]. Given the
important role of immune surveillance for metastasis, its
therapeutic modulation in the setting of metastatic
disease, and its interplay with SABR, evaluating the im-
portance of host immunity in the context of oligometasta-
sis ablation is warranted to explore useful predictive and/
or prognostic biomarkers.
Analysis
We aim to analyze peripherally circulating immune cells
for expression of surface antigens that are reflective of
immune activation or exhaustion/suppression. The ana-
lysis itself will be conducted by the Amsterdam UMC.
Samples will be collected and stored at each participat-
ing institution as per the Laboratory Manual and stored
at − 80 °C will subsequently be shipped, on an annual
basis, on dry ice to VU Amsterdam for further process-
ing and FACS analysis.
Tumor DNA analysis
Recent studies utilizing contemporary genomic analysis
techniques have identified individual gene-level alter-
ations (e.g., mutations and copy-number variations) as
well as genome-scale metrics (e.g., tumor mutational
burden and percent genomic copy-number alteration)
that correlate with metastatic disease and poor outcomes
[25, 28, 30, 31]. Perhaps most informatively, multi-
region sequencing of primary tumors and paired metas-
tases has permitted phylogenetic analysis of metastasis
evolution, shedding light on genetic alterations that cor-
relate with patterns of metastatic dissemination; specific-
ally, select genetic alterations in the setting of renal
cancer effectively differentiate a rapid, multi-site “poly-
metastatic” progression from an attenuated, indolentmetastatic disease course reminiscent of an oligometa-
static natural history [30]. These large-scale studies have
performed whole-genome sequencing in each patient, an
approach that is not currently practical or cost-effective
in the clinical setting. However, curating the findings of
these large-scale analyses to develop a targeted approach
using a panel-based subset of frequently-altered genetic
loci will permit a more focused yet rationally-based
evaluation of oligometastatic tumor DNA, akin to the
approach taken by Abbosh et al. [28].
Analysis
The plasma fraction containing circulating tumor DNA
(ctDNA) will be isolated from peripheral blood collected
at the above-mentioned timepoints as per the protocol
detailed in the Laboratory Manual. Once extracted,
plasma samples will be frozen at -80 C. Participating in-
stitutions will batch-ship frozen samples on dry ice to
LHSC where all samples will be stored.
Confidentiality
The names and personal information of study partici-
pants will be held in strict confidence. All study records
(case report forms, safety reports, correspondence, etc.)
will only identify the subject by initials and the assigned
study identification number. The investigator will main-
tain a confidential subject identification list (Master List)
during the course of the study. Access to confidential
information (i.e., source documents and patient records)
is only permitted for direct subject management and for
those involved in monitoring the conduct of the study
(i.e., Sponsors, CRO’s, representatives of the IRB/REB,
and regulatory agencies). The subject’s name will not be
used in any public report of the study.
Data sharing statement
Deidentified participant data from this trial will not be
shared publicly, however, the full protocol will be pub-
lished along with the primary analysis of the outcomes.
Protocol ammendments and trial publication
Any modifications to the trial protocol must be approved
and enacted by the principal investigator (Current version:
1.0 on January 31, 2018). Protocol amendments will
communicated to all participating centres, investigators,
IRBs, and trial registries by the principal investigator. Any
communication or publication of trial results will be led
by the principal investigator, and is expected to occur
within 1 year of the primary analysis. Trial results will
remain embargoed until conference presentation of an
abstract or until information release is authorized.
Authorship of the trial abstract and ultimately the full
manuscript will be decided by the principal investigator at
Palma et al. BMC Cancer          (2019) 19:816 Page 13 of 15the time of submission. Professional writers will not be
used for either abstract or manuscript preparation.
Discussion
The oligometastatic paradigm posits the existence of an
intermediate state between localized and widely-
disseminated metastatic cancer [1]. In this setting, resection
or ablative therapy to metastases is associated with better-
than-expected survival [2, 3]. Recent randomized data have
helped to confirm the existence of the oligometastatic state
and demonstrate that ablative therapy - including stereotac-
tic ablative radiotherapy (SABR) - improves progression-
free and overall survival [6, 7]. These studies are based
mostly on patients with 3 or fewer metastases; while SABR
is generally safe, the risk of treatment-related toxicity is
expected to rise with the number of metastases treated.
Therefore, considerable equipoise remains as to whether
patients with a greater number of metastases would simi-
larly benefit from SABR to all sites. It is incumbent upon
physicians to determine how many lesions are amenable to
safe, minimally-toxic ablative therapy that benefits the
oligometastatic patient. Furthermore, a practical definition
of oligometastatic disease will be aided by a deeper under-
standing of its biological underpinnings, which thus far
have remained elusive [22–24]. Identifying biomarkers
associated with a relatively indolent, sequential pattern of
progression (i.e., oligometastasis) will thus facilitate greater
accuracy in selecting which oligometastatic patients are
most likely to benefit from SABR.
The SABR-COMET-10 trial is a multicenter, inter-
national phase III trial that aims to accrue 159 patients
with 4–10 metastases, randomized to standard of care
versus standard of care plus SABR to all metastatic le-
sions. The delivery of SABR in this trial will be guided
by key principles including pre-planning prior to enrol-
ment to ensure safety, SABR dose reduction and strict
adherence to OAR tolerances to minimize toxicity, and
treatment completion within 2 weeks to prevent delay in
systemic therapy initiation/resumption. The primary
endpoint of SABR-COMET-10 is OS with secondary
endpoints of PFS and QoL. Translational endpoints will
also be assessed using peripheral blood samples collected
at multiple timepoints to evaluate circulating tumour
DNA, circulating tumour cells, and host immune cell
activation. Thus, SABR-COMET-10 aims to determine
both whether SABR improves outcomes in patients with
> 3 metastases as well as to identify biomarkers of oligo-
metastasis that can help select those patients who are
most likely to benefit.
This trial has several important limitations. Inclusion
of all histologies allows for more rapid accrual and
reduces the risk of failure due to poor enrollment, but
will not allow us to elucidate differences in outcomes by
histologic subtype. In addition, our estimate of a 10-month survival in the control arm is based on the results
of the original SABR-COMET trial, wherein patients
with 4–5 metastases in the control arm had a median
survival of only 7 months. We inflated this estimate to
10months, to increase our power to detect a difference
if outcomes have improved based on improvements in
standard of care systemic therapy since the original trial.
If the true survival in the standard arm is substantially
longer, then statistical power might be reduced. As in
the original SABR-COMET trial, in SABR-COMET-10
there is no specified limit to the number of lesions that
can be treated with palliative local treatments (such as
external beam radiation) on the standard arm. Ablative
treatments are not expected to be provided in Arm 1,
unless considered standard of care (e.g. stereotactic radi-
ation for brain metastases), and all such treatments de-
livered will be documented. We are optimistic that the
pragmatic components of this trial, the large number of
participating centres, and the presence of physician equi-
poise on this question will help to reduce the risk of
poor accrual.
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